[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-453619-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-453619-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","editoriala-milestone-in-the-technological-development-of-hadrontherapy-in-france","Editorial–A Milestone in the Technological Development of Hadrontherapy, in France","","Editorial on the symposium “Hadrontherapy for Life” held in Caen, France (March 10–11, 2025) marking the end of assembly work for the accelerator “C400” for hadrontherapy research and treatment. Summarizes the international community’s clinical experience and planned dissemination, while describing the cryogenic superconducting cyclotron concept, its European development history, and the final design goals. Outlines program planning at CYCLHAD, projected ramp-up timing, and mid-2026 beam expectations tied to the next PTCOG congress.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/editoriala-milestone-in-the-technological-development-of-hadrontherapy-in-france/453619/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/editoriala-milestone-in-the-technological-development-of-hadrontherapy-in-france/453619.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What symposium and dates marked the C400 milestone in hadrontherapy?","Question",{"text":63,"@type":64},"The symposium “Hadrontherapy for Life” was held in Caen, France, on March 10 and 11, 2025 to mark the end of assembly work for the C400 accelerator.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the C400 and what performance targets does it aim to provide?",{"text":68,"@type":64},"C400 is described as a 400 MeV/u cryogenic isochronous cyclotron intended to be compact and implantable in a hospital-based confined environment, producing heavy-ion beams from protons to carbon ions at clinically relevant energies and intensities.",{"name":70,"@type":61,"acceptedAnswer":71},"When are first C400 beams expected and what related meeting is referenced?",{"text":72,"@type":64},"First C400 beams are expected mid-2026, timed around the next annual “PTCOG 64” congress in Caen/Deauville.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},453619,1790937613,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":55,"preview_page_count":4},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","International Journal of Particle Therapy 19 (2026) 101288  \nContents lists available at ScienceDirect  \nInternational Journal of Particle Therapy  \njournal [homepage:](homepage: www.sciencedirect.com/journal/ijpt)[ www.sciencedirect.com/journal/ijpt](homepage: www.sciencedirect.com/journal/ijpt)  \nEditorial–A Milestone in the Technological Development of Hadrontherapy, in FranceHadrontherapy, cryogenic cyclotron  \nThe symposium “Hadrontherapy for Life,” which was held in Caen, France, on March 10 and 11, 2025, was to mark the end of the assembly work of the highly innovative accelerator “C400″ for research and treatment in hadrontherapy. Co-organized by the University of CaenNormandy, the Proton Therapy Center “CYCLHAD,” the François Baclesse Comprehensive Cancer Center and the Normandy Region, it was held at the University of Caen-Normandy, campus one, and hosted 150 or so experts from the international community.  \nThe objective of this symposium was primarily educational in synthetizing the experience of the international community (mainly Japanese and European) in the clinical (but not exclusively) setting and further disseminate data through published reports. You might enjoy some of them in this issue. It was also a unique opportunity to unveil the prototype of a new concept of accelerator for particle radiotherapy, a rare event in a scientist or physician career!.  \nThis equipment, the “C400″ superconducting cyclotron for heavy ions is not exactly a newcomer. Making a long story short, the concept was in the air since 1987 when the EULIMA European initiative chaired by its French designer Pierre MANDRILLON, a physicist and engineer trained at CERN, Head of the Cyclotron Laboratory in Nice, conducted a comparative investigation between this elegant approach and the more conventional synchrotron.1 Despite its attractiveness ([esp. in](esp. in) terms ofcompacity) and due to the formidable technological challenge it represented at that time, the latter was favored although no concrete project came true.2 The misfortune of EULIMA benefited national programs, all based on synchrotrons in Germany (HIT, Heidelberg and MIT, Marburg), Austria (MedAustron, Wiener Neustadt), Italy (CNAO, Pavia), and France (ETOILE, Lyon). Meanwhile, Yves JONGEN, Pierre MANDRILLON’s former colleague, physicist, engineer, founder and CEO of the Belgian IBA proton therapy company had revisited the “C400″ design and its feasibility, a collaborative effort with the physics group at JINR-Dubna.3 But the mountain was still too high for a single mountaineer to climb, and the wind turned again: the ETOILE project, short of money, was shut down in the mid-2010s. A competitor was born atthe GANIL nuclear research center in Caen in 2003 with an attractive project mixing physicists, engineers, biologists, and eventually clinicians under the acronym of ASCLEPIOS, and later ARCHADE. Importantly, this project was strongly supported by the University and financed by the governance of the region of Normandy, which is sort of Mecca for the French civil and military nuclear industry since the early 70 seconds. The saga approaches the end with the creation by the Normandy-Region of a multinational consortium of French, Belgian (of course!) and other European industrials and stakeholders supported by European banks: The Normandy-Hadrontherapy group.  \nLet’s introduce you the final design of “C400″: a 400 MeV/u cryogenic isochronous cyclotron, compact and implantable in a confined environment (ie, hospital-based) with its 3.5 m radius (less than a third of a conventional synchrotron), able to produce a wide range of heavy particles (at least from protons to carbon ions) at clinically relevant beams energy, intensity, and size, and supposedly available on the market at reasonable price and running cost. It will join at the CYCLHAD Proton Therapy Center, an existing “ProteusONE” singleroom solution for proton-therapy (PT). As far as we know, no alternative, technological ","cbCaikXNtgoTyfnU","https://ap.wps.com/l/cbCaikXNtgoTyfnU","pdf",447965,"English","# Editorial–A Milestone in the Technological Development of Hadrontherapy, in France\n## Symposium purpose and international dissemination\n## Development history of C400 and accelerator prototypes\n## Final design, CYCLHAD integration, and clinical program timeline\n## Expected first beams and upcoming PTCOG congress","[{\"question\":\"What symposium and dates marked the C400 milestone in hadrontherapy?\",\"answer\":\"The symposium “Hadrontherapy for Life” was held in Caen, France, on March 10 and 11, 2025 to mark the end of assembly work for the C400 accelerator.\"},{\"question\":\"What is the C400 and what performance targets does it aim to provide?\",\"answer\":\"C400 is described as a 400 MeV/u cryogenic isochronous cyclotron intended to be compact and implantable in a hospital-based confined environment, producing heavy-ion beams from protons to carbon ions at clinically relevant energies and intensities.\"},{\"question\":\"When are first C400 beams expected and what related meeting is referenced?\",\"answer\":\"First C400 beams are expected mid-2026, timed around the next annual “PTCOG 64” congress in Caen/Deauville.\"}]","Editorial–A Milestone in the Technological Development of Hadrontherapy, in France | PDF",1790739234]